For the other claims, the applicant provided only background evidence, specifically retrospective studies, which describe findings for a predicate device, the Axoguard Nerve Protector TM , which received FDA 510(k) clearance on January 10, 2014, not the nominated device, the Axoguard HA+ Nerve Protector TM
The goal of long-term therapy is maintaining optimal glutathione status to support cellular resilience against ongoing oxidative challenges rather than achieving supraphysiological effects
Urz, O., Olofsson Bagge, R
The future may hold medicines that prevent chronic diseases before they start, aiming for longer, healthier lives rather than just treating illness when it appears
Hyperalgesia: a dramatic or severe pain in response to a stimulus that normally causes mild pain
Esta gua tiene fines exclusivamente informativos